Free Trial

Truist Financial Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Genmab A/S logo with Medical background

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its price objective lifted by analysts at Truist Financial from $45.00 to $46.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Truist Financial's target price would indicate a potential upside of 110.43% from the stock's current price.

GMAB has been the subject of a number of other reports. HC Wainwright reissued a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. William Blair raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Wall Street Zen downgraded shares of Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.80.

View Our Latest Research Report on Genmab A/S

Genmab A/S Stock Up 1.3%

Shares of NASDAQ:GMAB traded up $0.28 during midday trading on Tuesday, hitting $21.86. 1,049,321 shares of the stock traded hands, compared to its average volume of 1,243,369. The stock has a market capitalization of $14.02 billion, a PE ratio of 12.42, a P/E/G ratio of 6.73 and a beta of 0.94. The business's 50 day moving average is $21.02 and its two-hundred day moving average is $20.73. Genmab A/S has a one year low of $17.24 and a one year high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The company had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. As a group, sell-side analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after buying an additional 939 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares during the last quarter. Barclays PLC lifted its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Genmab A/S during the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines